CA2451932C - Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases - Google Patents

Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases Download PDF

Info

Publication number
CA2451932C
CA2451932C CA002451932A CA2451932A CA2451932C CA 2451932 C CA2451932 C CA 2451932C CA 002451932 A CA002451932 A CA 002451932A CA 2451932 A CA2451932 A CA 2451932A CA 2451932 C CA2451932 C CA 2451932C
Authority
CA
Canada
Prior art keywords
alkyl
ny1y2
compound according
heteroaryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002451932A
Other languages
English (en)
Other versions
CA2451932A1 (fr
Inventor
Paul J. Cox
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Christopher Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Iain Mclay
David Aldous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CA2451932A1 publication Critical patent/CA2451932A1/fr
Application granted granted Critical
Publication of CA2451932C publication Critical patent/CA2451932C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La présente invention se rapporte à des composés représentés par la formule (I) ainsi qu'à des N-oxydes, des promédicaments, des bioisostères acides, des sels ou solvates pharmaceutiquement acceptables de ces composés, ou des N-oxydes, des promédicaments ou des bioisostères acides de ces sels ou solvates. L'invention se rapporte également à des compositions contenant ces composés ainsi qu'à des procédés de traitement consistant à administrer, à un patient justiciable d'un tel traitement, ces composés et compositions.
CA002451932A 2001-06-23 2002-06-21 Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases Expired - Fee Related CA2451932C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
GB0115393.1 2001-06-23
US30167801P 2001-06-28 2001-06-28
US60/301,678 2001-06-28
PCT/GB2002/002835 WO2003000695A1 (fr) 2001-06-23 2002-06-21 Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases

Publications (2)

Publication Number Publication Date
CA2451932A1 CA2451932A1 (fr) 2003-01-03
CA2451932C true CA2451932C (fr) 2009-12-29

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002451932A Expired - Fee Related CA2451932C (fr) 2001-06-23 2002-06-21 Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases

Country Status (22)

Country Link
EP (1) EP1404676A1 (fr)
JP (1) JP4344607B2 (fr)
CN (1) CN1294135C (fr)
AU (1) AU2002314325B8 (fr)
BR (1) BR0210652A (fr)
CA (1) CA2451932C (fr)
CZ (1) CZ20033443A3 (fr)
EA (1) EA007415B1 (fr)
EC (1) ECSP034922A (fr)
EE (1) EE05432B1 (fr)
GB (1) GB0115393D0 (fr)
HU (1) HUP0400300A3 (fr)
ME (1) MEP19308A (fr)
NZ (1) NZ529766A (fr)
OA (1) OA12632A (fr)
PL (1) PL374096A1 (fr)
RS (1) RS51698B (fr)
SK (1) SK15882003A3 (fr)
TN (1) TNSN03144A1 (fr)
TR (1) TR200302242T2 (fr)
UA (1) UA76760C2 (fr)
WO (1) WO2003000695A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP1687309A1 (fr) 2003-11-17 2006-08-09 Pfizer Products Inc. Composés de pyrrolopyrimidine utiles dans le traitement du cancer
BRPI0416909A (pt) * 2003-11-25 2007-01-16 Pfizer Prod Inc método de tratamento de aterosclerose
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (fr) * 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (fr) 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2607901C (fr) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methodes et compositions pour le traitement de maladies osseuses degeneratives comprenant un compose inhibiteur syk 2,4-pyrimidinediamine
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP3495369B1 (fr) 2007-06-13 2021-10-27 Incyte Holdings Corporation Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
NZ586642A (en) 2008-01-11 2012-04-27 Natco Pharma Ltd Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
PE20140407A1 (es) 2008-06-10 2014-04-25 Abbott Lab Nuevos compuestos triciclicos
MX2011012262A (es) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak).
EA025520B1 (ru) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
WO2011018894A1 (fr) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
TW201802091A (zh) * 2009-12-01 2018-01-16 艾伯維有限公司 新穎三環化合物
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
CN102093364B (zh) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN103476776B (zh) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
DK2877467T3 (en) 2012-07-26 2017-02-13 Glaxo Group Ltd 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
JP6318156B2 (ja) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
EA030705B1 (ru) 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Способы и промежуточные соединения при получении ингибитора jak
AU2014244263A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. CDK9 kinase inhibitors
BR112015021549A2 (pt) 2013-03-13 2017-07-18 Abbvie Inc inibidores de piridina cinase cdk9
WO2014151444A1 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Inhibiteurs de pyrrolo[2,3-b]pyridine cdk9 kinase
AU2014231567A1 (en) 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
JP2016512560A (ja) * 2013-03-14 2016-04-28 アッヴィ・インコーポレイテッド ピロロピリミジン系ｃｄｋ９キナーゼ阻害薬
ES2792549T3 (es) 2013-08-07 2020-11-11 Incyte Corp Formas de dosificación de liberación sostenida para un inhibidor de JAK1
CN104804001B9 (zh) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
SG10201913986YA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2018165581A1 (fr) 2017-03-09 2018-09-13 Abbvie Inc. Procédés de traitement de la maladie de crohn et de la rectocolite hémorragique
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PL3746429T3 (pl) 2018-01-30 2022-06-20 Incyte Corporation Procesy do otrzymywania (1-(3-fluoro-2-(trifluorometylo)izonikotynoilo)piperydyn-4-onu)
WO2019191684A1 (fr) 2018-03-30 2019-10-03 Incyte Corporation Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
EP3860998B1 (fr) 2018-10-05 2023-12-27 Annapurna Bio Inc. Composés et compositions destinés au traitement d'états pathologiques associés à une activité du récepteur de l'apj
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
BR9713552A (pt) * 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
ID26698A (id) * 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CZ2001959A3 (cs) * 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
DK1235830T3 (da) * 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer

Also Published As

Publication number Publication date
CN1518552A (zh) 2004-08-04
ECSP034922A (es) 2004-04-28
JP2005508300A (ja) 2005-03-31
WO2003000695A1 (fr) 2003-01-03
RS99203A (en) 2006-12-15
TR200302242T2 (tr) 2004-12-21
EA007415B1 (ru) 2006-10-27
NZ529766A (en) 2008-11-28
MEP19308A (en) 2010-06-10
JP4344607B2 (ja) 2009-10-14
CN1294135C (zh) 2007-01-10
SK15882003A3 (sk) 2004-07-07
HUP0400300A3 (en) 2010-12-28
HUP0400300A2 (en) 2007-08-28
AU2002314325B8 (en) 2009-01-29
AU2002314325B2 (en) 2009-01-08
RS51698B (en) 2011-10-31
EE200400003A (et) 2004-02-16
EP1404676A1 (fr) 2004-04-07
CA2451932A1 (fr) 2003-01-03
BR0210652A (pt) 2004-08-10
EA200400073A1 (ru) 2004-08-26
PL374096A1 (en) 2005-09-19
GB0115393D0 (en) 2001-08-15
UA76760C2 (uk) 2006-09-15
TNSN03144A1 (en) 2005-12-23
EE05432B1 (et) 2011-06-15
CZ20033443A3 (en) 2004-03-17
WO2003000695A8 (fr) 2004-03-11
OA12632A (en) 2006-06-14

Similar Documents

Publication Publication Date Title
CA2451932C (fr) Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
AU2002314325A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
US7259154B2 (en) Pyrrolopyrimidines
CA2395593C (fr) Azaindoles
IL197381A (en) 2- [4- (7-ethyl-h5-pyrrolo [3,2- b] pyrene-6-ram) -phenyl] -propane-2-ol, pharmaceutical preparations containing it and use of drug preparation material
KR20140095477A (ko) 마크로시클릭 lrrk2 키나제 억제제
JP2010520294A (ja) 複素環式部分を含有するメタロプロテアーゼ阻害剤
KR20100120680A (ko) Ｐｉ３ｋ 저해제로서의 피롤로피리미딘 유도체 및 그의 용도
AU2003221500A1 (en) Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
WO2010070237A1 (fr) DÉRIVÉS DE 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE ET 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
ES2382759T3 (es) Azaindoles
EP3915990A1 (fr) Dérivés de 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide en tant qu'inhibiteurs de limk et/ou rock kinases pour le traitement du cancer
WO2024067445A1 (fr) Nouvel inhibiteur de prmt5 et son utilisation
ZA200309315B (en) Pyrrolopyrimidines as protein kinase inhibitors.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130621